Background: It is unclear if traditional histopathology and noninvasive blood-based tests are sufficiently accurate to detect cytomegalovirus (CMV)
viremia and have shown to be useful to guide pre-emptive antiviral therapy in transplant recipients. 14, 15 However, it remains to be elucidated whether these tests are sensitive and specific enough to be clinically useful when assessing CMV reactivation in IBD.
Much of the uncertainty related to the diagnostic accuracy of these tests results from studies with small sample sizes and heterogeneous methodologies, which make it difficult to draw firm conclusions. Therefore, the purpose of this study is to examine the diagnostic accuracy of noninvasive blood tests and histopathology compared with the IHC and tPCR in patients with IBD.
METHODS
This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines (Appendix 1). 16 The Cochrane handbook and diagnostic accuracy study reviews were used to guide the analysis. [17] [18] [19] The study followed an a priori established protocol.
Search Strategy and Study Selection
A systematic search of multiple electronic databases (Embase, Medline [OvidSP] , Cochrane Central Register of Controlled Trials, Cochrane Database of Abstracts of Reviews of Effects, Web of Science, Medline [Pubmed]) was conducted from inception through January 1st, 2016 under the guidance of a trained medical librarian. The following MeSH descriptors were included: "Cytomegalovirus" or "CMV" and "Inflammatory Bowel Disease" or "IBD" or "ulcerative colitis" or "Crohn's Disease." The bibliographies of included studies and recent review articles were also searched to identify additional studies. Only studies published in English were included in our literature review.
Two investigators (P.T. and J.D.M.) independently reviewed the titles and abstracts of each study, and those deemed to match the predefined inclusion criteria were reviewed in full. Disagreement was resolved through discussion.
Observational studies (case-control and cross-sectional), including abstracts, assessing CMV reactivation by 2 or more diagnostic techniques, were deemed acceptable. Inclusion criteria included (1) patients with an established diagnosis of IBD (UC, Crohn's disease or IBD undifferentiated), (2) studies assessing CMV reactivation by 2 or more of the following: H&E, IHC, tPCR, bPCR, pp65 antigenemia assay, and (3) at least one diagnostic test required a tissue-based technique by IHC or tPCR. Studies that used nested PCR, included 5 or fewer patients diagnosed with CMV, or had insufficient data to calculate true positive, and true negative values were excluded.
Study Definitions and Endpoints
The primary outcomes were the diagnostic accuracies of blood-based tests and H&E histopathology for predicting colonic CMV reactivation compared with IHC and tPCR. A blood-based test was defined as either bPCR or pp65 antigenemia assay. Thresholds for positive PCR techniques could not be standardized because of study variability. An exploratory analysis was also performed to compare the sensitivity of IHC with tPCR.
To assess potential sources of heterogeneity, multiple preplanned subgroup analyses were performed, including: (1) the type of blood-based test (bPCR versus pp65 antigenemia); (2) the type of tissue-based test (IHC versus tPCR); (3) the study location (Western versus Asian); and (4) the study design (prospective versus retrospective and cross-sectional versus case-control). Western studies included countries in Europe and North America. A sensitivity analysis was also performed to exclude studies using colectomy specimens.
Data Extraction and Study Quality
Two investigators (P.T. and J.D.M.) independently abstracted the following data: (1) baseline study characteristics-primary author, title of publication, year of publication, geographical location of patient population, and study design; (2) IBD characteristics-the number of patients with UC or Crohn's disease, disease state (inactive colitis versus disease exacerbation), and the proportion of patients with medically refractory disease; (3) specimen type-colonic biopsies versus colectomy specimen; (4) diagnostic test-blood-based (pp65 antigenemia or bPCR), tissue-based (H&E, IHC, or tPCR); and (5) the proportion of positives and negatives for each diagnostic test.
Study quality was determined by the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. 20, 21 We used the standard 4 QUADAS-2 domains: patient selection, index test, reference standard, and flow/timing. The patient population was defined as patients with IBD, the target condition was CMV reactivation, and the index test and reference tests were defined as any positive blood-based or tissue-based test. The overall risk of bias was evaluated for all 4 domains. The flow/timing domain was excluded for applicability analysis. Each study was assigned an overall judgment of "low," "high," or "unclear" risk by both authors, and all discrepancies were resolved by consensus.
Statistical Analysis
OpenMeta version 10.10, Review Manager 5.3, and SAS 9.3 were used for statistical analysis. [22] [23] [24] Sensitivity and specificity were calculated for each of the available comparisons. Coupled sensitivity and specificity forest plots along with receiver operating characteristics (SROC) curves were generated for the primary outcomes. The paired forest plots were sorted in hierarchical format by decreasing sensitivity to allow visual assessment for "threshold effect." 18 Summary estimates from weighted studies were determined for sensitivity and specificity using bivariate analysis with random effects modeling. Both model-fit analysis and number of studies (less than 5) were applied to generate summary estimates by the bivariate fixed-effect model.
RESULTS

Study Search Results and Characteristics
A total of 1901 citations were identified from our initial database search. Based on abstract review, a total of 83 studies were selected for full-length manuscript evaluation. After applying our inclusion and exclusion criteria, 16 citations were included. 5, 7, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The coefficient of agreement between reviewers for article selection was 0.84 (95% confidence interval [CI], 0.70-0.97). Figure 1 depicts the study flow.
Study characteristics are summarized in Table 1 . Of the studies that were published from 2004 to 2015, 14 studies were full-length manuscripts, 5, 7, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 37 and 2 studies were abstracts from conference proceedings. 36, 38 Nine studies were prospective, 5, 7, [25] [26] [27] [28] [29] 33, 36 and 7 studies were retrospective. [30] [31] [32] 34, 35, 37, 38 All 16 studies included data from noncolectomy specimens, 5, 7, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] of which 1 study also included data from colectomy specimens. 32 All patients from the noncolectomy studies had active disease; 14 studies included patients with severe colitis, 7,25-33,35-38 and 4 included patients with corticosteroid-refractory disease. 26, 28, 32, 33 Seven studies reported obtaining biopsies from inflamed tissue such as ulcerated lesions, 5, 7, 27, 29, 32, 33, 37 whereas the others did not specifically report biopsy location. Eight studies included patients from Western countries 7, [26] [27] [28] 30, 32, 34, 36 and 7 studies with patients from Asian countries. 5, 25, 29, 31, 35, 37, 38 
Blood-Based Tests for Predicting Colonic CMV Reactivation
Nine studies assessed the diagnostic accuracy of bloodbased tests for predicting CMV reactivation compared with IHC or tPCR 7, [26] [27] [28] [29] 31, [36] [37] [38] : 5 studies by pp65 antigenemia 28, 29, 31, 37, 38 and 4 studies by bPCR 7, 26, 27, 36 (Fig. 2, Table 2 , and see Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B475, which demonstrates the SROC curve for the diagnostic accuracy of blood-based tests compared with IHC or tPCR). The sensitivity of blood-based tests ranged from 7.0% to 90% (Fig. 2) . Visual assessment of the paired sensitivity and specificity plots revealed no evidence of threshold effect. The overall pooled sensitivity of blood-based tests was 50.8% (95% CI, 19.9-81.6); 39.7% (95% CI, 27.4-52.1) for pp65 antigenemia assay, and 60.0% (95% CI, 46.5-73.5) for bPCR. The overall pooled specificity of bloodbased tests was 99.9% (95% CI, 99-100); 90.7% (95% CI, 86.1-95.4) for pp65 antigenemia assay, and 100% for bPCR. The sensitivity and specificity of blood-based tests remained stable in the subgroup analysis according to study type (prospective versus retrospective and cross-sectional versus case-control) and geographical location (Western versus Asian). Finally, the positive predictive value (PPV) and negative predictive value of blood-based testing for predicting colonic CMV reactivation were 83.8% (95% CI, 58.6-95.0) and 80.3% (95% CI, 69.8-87.7), respectively.
Next, we determined the accuracy of blood-based tests for predicting colonic CMV reactivation compared with IHC or tPCR; 5 studies by IHC 7,27,28,31,38 and 6 studies by tPCR 7, 26, 27, 29, 36, 37 (Table 2 ). The sensitivity of blood-based tests was numerically lowest for predicting CMV reactivation by tPCR (39.6%; 95% CI, 2.1-77.1). When compared with IHC, the sensitivity was 78.6% (95% CI, 64.5-92.7). Specificity remained high for blood-based tests in predicting tPCR (100%) or IHC (86.0%; 95% CI, 81.0-90.9). A single study assessed the diagnostic accuracy of blood-based tests based on the degree of viral burden. 6 When using a cutoff of 5 or more inclusions by IHC to indicate high viral burden, bPCR had a sensitivity of 14% in patients with a low viral burden and 50% in patients with a high viral burden. 6 
Comparison of Individual Tissue-Based Tests for CMV Reactivation
Nine studies assessed the sensitivity of H&E for CMV reactivation compared with IHC or tPCR: 5 studies by IHC [28] [29] [30] 32, 33 and 4 studies by tPCR 5, 7, 25, 29 (Fig. 3A-C , and see Fig. 2 , Supplemental Digital Content 2, http://links.lww. com/IBD/B476, which demonstrates the SROC curve for the diagnostic accuracy of histopathology compared with IHC or tPCR). The overall pooled sensitivity of H&E for CMV reactivation was 12.5% (95% CI, 3.6-21.4); 34.6% when compared with IHC as the reference test (95% CI, 13.8-55.4), and 4.7% when compared with tPCR as the reference test (95% CI, 1.2-17.1). The overall pooled specificity of H&E for CMV reactivation was 99.1% (95% CI, 97.9-100); 99.2% (95% CI, 97.5-100) when compared with IHC as the reference test, and 98.1% (95% CI, 94.2-99.4) when compared with tPCR as the reference test. The PPV and negative predictive value of H&E for predicting colonic CMV reactivation was 77.4% (95% CI, 47.9-92.8) and 56.4% (95% CI, 23.3-84.6), respectively. Two studies assessed the diagnostic accuracy of H&E histopathology based on the degree of viral burden. 6, 7 When using a cutoff of 5 or more inclusions by IHC to indicate high viral burden, H&E was found to have a sensitivity of 18% in patients with a low viral burden and 44% in patients with a high viral burden. 6 In a second study, all patients were negative by H&E, including those with a high viral burden (defined as greater than 250 viral copies/mg tissue PCR). 7 Finally, we performed an exploratory analysis to assess the sensitivity of IHC compared with tPCR as the reference standard. When compared with tPCR (3 studies), 7, 27, 29 IHC had a sensitivity and specificity of 23.0% (95% CI, 8.8-48.0) and 98.7% (95% CI, 93.9-99.7), respectively.
Quality Assessment
The quality of studies included in this analysis is listed in Table 3 . Overall, only 1 study was deemed high-risk for bias. When individual components of the QUADAS-2 were assessed for risk of bias, 6 studies were considered low-risk for patient selection, 7 studies were considered low-risk for reference standard, and 12 studies were considered low-risk for flow and timing. There were no studies that were assessed as low-risk for the index test domain. In all other studies, the risk of bias was deemed uncertain. When assessing concerns for applicability, 9 studies demonstrated no concern for patient selection, 15 studies demonstrated no concern for the use of the index test, and 14 studies demonstrated no concern for the use of the reference standard test. 
DISCUSSION
CMV reactivation is a potentially reversible process and is associated with poor clinical outcomes in certain high-risk patients with IBD. 6, 9 Therefore, a prompt and accurate diagnosis of CMV is critical, particularly in medically refractory patients. Here, we demonstrate that although blood-based tests (pp65 and bPCR) have a reasonable PPV, they are not sensitive enough to reliably predict colonic CMV reactivation in IBD. Similarly, histopathology is also not sufficiently sensitive to detect CMV reactivation in IBD.
Noninvasive blood-based tests are used routinely to guide empiric antiviral therapy in transplant recipients suspected of having CMV reactivation. [39] [40] [41] By contrast, this study demonstrates that detection of systemic CMV may not be as useful in patients with IBD if used as a sole diagnostic test. This apparent disease-specific disparity may be related to differences in the degree of immunosuppression, the type of end-organ involvement, and/or differences in the rates of primary CMV infection, particularly in transplant recipients of CMV-positive grafts. In contrast to their poor sensitivity, blood-based tests are highly specific and have a reasonable PPV, suggesting that a positive test could obviate the need for an invasive endoscopic exam.
However, it is also important to consider that CMV viremia can occur transiently without the need for antiviral therapy, 42 and it remains unclear if blood-based tests can adequately predict the degree of viral burden within colonic mucosa, an important determinant of pathogenicity and response to antiviral therapy. 6, 7 Therefore, until these issues are resolved, blood-based testing alone should not replace a tissue-based diagnosis. However, blood-based tests may serve as an important adjunct to tissuebased tests for predicting colectomy risk and to determine when immunosuppressive therapy should be held. 10, 11 This study demonstrated the poor sensitivity of H&E compared with IHC and tPCR. A possible explanation for this finding is that CMV reactivation may not produce the typical histologic "owls-eye" appearance in IBD. 43 Alternatively, the poor sensitivity of H&E may be related to a "needle in a haystack" phenomenon in situations of low-grade CMV reactivation. Even with high-grade CMV reactivation, defined by 5 or more nuclear inclusions by IHC 6 or greater than 250 viral copies/mg tissue by tPCR, 7 H&E had poor sensitivity. 6, 7, 34 Therefore, H&E alone has a limited role in excluding CMV reactivation.
In an exploratory analysis, IHC seemed to have poor sensitivity compared with tPCR as the reference standard. We suspect that this is related largely to the cutoffs used to define a positive test. However, it remains unclear if these differences in sensitivity are clinically relevant. On the one hand, tPCR may be a truly superior test for detecting CMV disease; alternatively, the incremental benefit of tPCR over IHC may simply be in detecting an "innocent bystander." 44 Further studies are required to compare these tests using standardized definitions of clinically relevant CMV disease. It is important to acknowledge that we considered any degree of CMV reactivation as being positive for our overall analysis because even low levels of CMV reactivation may have clinical relevance for prognostication and treatment decisions. We previously demonstrated that patients with a low viral burden had poor responses to antiviral therapy and high rates of colectomy. 6 Furthermore, when an escalation of immunosuppression is required in the setting of low levels of CMV reactivation, anti-tumor necrosis factor agents may be the treatment of choice compared with corticosteroids. 9, 45 While low levels of CMV may have implications on clinical outcomes, the impact of antiviral therapy may be most pronounced with higher thresholds of CMV reactivation. "Clinically relevant" CMV is a term we use to indicate when patients are likely to benefit from antiviral therapy, a concept that is likely dependent on the degree of viral burden and the patient's initial response to immunosuppressive therapy. 6, 7, 9 A number of studies have attempted to quantify the degree of viral burden to predict "clinically relevant CMV". 6, 7, 46 Jones and colleagues determined that patients with 5 or more inclusions by IHC were more likely to respond to antiviral therapy. 6 Similarly, Pillet and colleagues recently validated cutoff values for tPCR to predict clinically relevant CMV disease. 46 Unfortunately, we were unable to use these cutoffs to determine the overall diagnostic accuracy of histopathology and blood-based tests. However, we were able to perform subgroup analyses using IHC alone, which may be a more specific test for "clinically relevant disease." In these analyses, blood-based tests had reasonable sensitivity for predicting colonic CMV reactivation, whereas H&E histology remained an insensitive test for detecting colonic CMV reactivation.
There are a number of limitations to our study. First was the definition of our gold standard. Although, IHC and tPCR are proposed gold standards by multiple societies, 10,11 variability exists in the types of assays available commercially, and the thresholds used to denote a positive test. We attempted to limit false positive testing by excluding studies that used nested PCR, an overly sensitive diagnostic test. However, it remains possible that these gold standards, particularly tPCR, have the ability to detect low levels of CMV with questionable clinical relevance. Second, standardized protocols for diagnostic testing are lacking; therefore, it is likely that variability existed between institutions with respect to biopsy number, and biopsy location (ulcerated versus nonulcerated mucosa). We previously demonstrated that biopsy number impacts the sensitivity of IHC in detecting CMV. 34 In this study, it was concluded that at least 11 biopsies in UC, and 16 biopsies in Crohn's disease are required to maintain a high degree of sensitivity for detecting CMV by IHC. 34 Finally, although only one study was deemed high-risk for bias based on the QUADAS-2 assessment, the risk of bias was uncertain in a number of studies. This was driven largely by the lack of an a priori design to assess diagnostic accuracy, and our inability to control for disease severity, corticosteroid exposure, patient age, and comorbidities.
In summary, our study demonstrates that there are substantial differences in sensitivity between commercially available tests for CMV. There are limitations for each, and caution should be taken when selecting the most appropriate diagnostic test. Based on the available data, we recommend against H&E histopathology as a sole diagnostic test when assessing CMV reactivation in IBD. Although blood-based tests may have clinical utility when positive, a negative test in isolation should not be relied on to exclude CMV disease. Therefore, we recommend either IHC or tPCR when assessing CMV reactivation in IBD. Further studies are needed to determine which of these tests is the most accurate and cost effective one for detecting "clinically relevant" CMV disease. 7 
RESULTS
Study selection 17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Study characteristics 18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Results of individual studies 20. For all outcomes considered (benefits or harms), present, for each study: (1) simple summary data for each intervention group (2) effect estimates and confidence intervals, ideally with a forest plot. Table 2 DISCUSSION Summary of evidence 24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers).
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Limitations 25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e. g., incomplete retrieval of identified research, reporting bias). 
